1. Newer and better agents are becoming available each year. How does this influence when a patient should be switched to insulin? 2. Newer insulins vs. standard, time-tested therapies: advantages and disadvantages. 3. Oral and inhaled insulins: Will they have a place in therapy? 4. Complications: macrovascular and microvascular. 5. How much of the risk is glycemic control vs. genetic susceptibility?